Davelizomib

N/A

Report date: 2025/03/26 16:55:25
NME

Base Information

Drug NameDavelizomib
Drug Alias NameTQB-3820
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionZinc finger protein Aiolos degradersDNA-binding protein Ikaros degraders
TargetsZinc finger protein AiolosDNA-binding protein Ikaros
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A